Literature DB >> 9184808

Neurochemical actions of vigabatrin and tiagabine alone and in combination in mouse cortex.

J P Leach1, G J Sills, E Butler, G Forrest, G G Thompson, M J Brodie.   

Abstract

1. The effects of repeated administration of the anticonvulsant compounds, vigabatrin (VGB) and tiagabine (TGB), on gamma-aminobutyric acid (GABA) concentration and the activities of GABA-transaminase (GABA-T) and glutamic acid decarboxylase (GAD) were investigated in mouse cortex. 2. VGB alone increased GABA levels and decreased GABA-T and GAD activities. 3. TGB alone was essentially without effect. 4. Low doses of VGB and TGB in combination increased GABA levels when neither drug had such an effect alone. 5. Despite this observation, this study failed to establish any conclusive evidence for an interaction between VGB and TGB that might help to explain their reported clinical synergism.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9184808     DOI: 10.1016/s0306-3623(96)00357-6

Source DB:  PubMed          Journal:  Gen Pharmacol        ISSN: 0306-3623


  4 in total

1.  Effects of γ-Aminobutyric acid transporter 1 inhibition by tiagabine on brain glutamate and γ-Aminobutyric acid metabolism in the anesthetized rat In vivo.

Authors:  Anant B Patel; Robin A de Graaf; Douglas L Rothman; Kevin L Behar
Journal:  J Neurosci Res       Date:  2015-02-06       Impact factor: 4.164

2.  Inhibition of uptake, steady-state currents, and transient charge movements generated by the neuronal GABA transporter by various anticonvulsant drugs.

Authors:  U Eckstein-Ludwig; J Fei; W Schwarz
Journal:  Br J Pharmacol       Date:  1999-09       Impact factor: 8.739

3.  Effects of blocking GABA degradation on corticotropin-releasing hormone gene expression in selected brain regions.

Authors:  V Tran; C G Hatalski; X X Yan; T Z Baram
Journal:  Epilepsia       Date:  1999-09       Impact factor: 5.864

4.  Neuropharmacological and neurobiological relevance of in vivo ¹H-MRS of GABA and glutamate for preclinical drug discovery in mental disorders.

Authors:  Conny F Waschkies; Andreas Bruns; Stephan Müller; Martin Kapps; Edilio Borroni; Markus von Kienlin; Markus Rudin; Basil Künnecke
Journal:  Neuropsychopharmacology       Date:  2014-04-03       Impact factor: 7.853

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.